FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2102393399> ?p ?o ?g. }

• W2102393399 endingPage "122" @default.
• W2102393399 startingPage "115" @default.
• W2102393399 abstract "BackgroundSmall benign insulinomas are hard to localise, leading to difficulties in planning of surgical interventions. We aimed to prospectively assess the insulinoma detection rate of single-photon emission CT in combination with CT (SPECT/CT) with a glucagon-like peptide-1 receptor avid radiotracer, and compare detection rates with conventional CT/MRI techniques.MethodsIn our prospective imaging study, we enrolled adults aged 25–81 years at centres in Germany, Switzerland, and the UK. Eligible patients had proven clinical and biochemical endogenous hyperinsulinaemic hypoglycaemia and no evidence for metastatic disease on conventional imaging. CT/MRI imaging was done at referring centres according to standard protocols. At three tertiary nuclear medicine centres, we used whole body planar images and SPECT/CT of the abdomen up to 168 h after injection of 111In-[Lys40(Ahx-DTPA-111In)NH2]-exendin-4 (111In-DTPA-exendin-4) to identify insulinomas. Consenting patients underwent surgery and imaging findings were confirmed histologically.FindingsBetween Oct 1, 2008, and Dec 31, 2011, we recruited 30 patients. All patients underwent 111In-DTPA-exendin-4 imaging, 25 patients underwent surgery (with histological analysis), and 27 patients were assessed with CT/MRI. 111In-DTPA-exendin-4 SPECT/CT correctly detected 19 insulinomas and four additional positive lesions (two islet-cell hyperplasia and two uncharacterised lesions) resulting in a positive predictive value of 83% (95% CI 62–94). One true negative (islet-cell hyperplasia) and one false negative (malignant insulinoma) result was identified in separate patients by 111In-DTPA-exendin-4 SPECT/CT. Seven patients (23%) were referred to surgery on the basis of 111In-DTPA-exendin-4 imaging alone. For 23 assessable patients, 111In-DTPA-exendin-4 SPECT/CT had a higher sensitivity (95% [95% CI 74–100]) than did CT/MRI (47% [27–68]; p=0·011).Interpretation111In-DTPA-exendin-4 SPECT/CT could provide a good second-line imaging strategy for patients with negative results on initial imaging with CT/MRI.FundingOncosuisse, the Swiss National Science Foundation, and UK Department of Health. Small benign insulinomas are hard to localise, leading to difficulties in planning of surgical interventions. We aimed to prospectively assess the insulinoma detection rate of single-photon emission CT in combination with CT (SPECT/CT) with a glucagon-like peptide-1 receptor avid radiotracer, and compare detection rates with conventional CT/MRI techniques. In our prospective imaging study, we enrolled adults aged 25–81 years at centres in Germany, Switzerland, and the UK. Eligible patients had proven clinical and biochemical endogenous hyperinsulinaemic hypoglycaemia and no evidence for metastatic disease on conventional imaging. CT/MRI imaging was done at referring centres according to standard protocols. At three tertiary nuclear medicine centres, we used whole body planar images and SPECT/CT of the abdomen up to 168 h after injection of 111In-[Lys40(Ahx-DTPA-111In)NH2]-exendin-4 (111In-DTPA-exendin-4) to identify insulinomas. Consenting patients underwent surgery and imaging findings were confirmed histologically. Between Oct 1, 2008, and Dec 31, 2011, we recruited 30 patients. All patients underwent 111In-DTPA-exendin-4 imaging, 25 patients underwent surgery (with histological analysis), and 27 patients were assessed with CT/MRI. 111In-DTPA-exendin-4 SPECT/CT correctly detected 19 insulinomas and four additional positive lesions (two islet-cell hyperplasia and two uncharacterised lesions) resulting in a positive predictive value of 83% (95% CI 62–94). One true negative (islet-cell hyperplasia) and one false negative (malignant insulinoma) result was identified in separate patients by 111In-DTPA-exendin-4 SPECT/CT. Seven patients (23%) were referred to surgery on the basis of 111In-DTPA-exendin-4 imaging alone. For 23 assessable patients, 111In-DTPA-exendin-4 SPECT/CT had a higher sensitivity (95% [95% CI 74–100]) than did CT/MRI (47% [27–68]; p=0·011). 111In-DTPA-exendin-4 SPECT/CT could provide a good second-line imaging strategy for patients with negative results on initial imaging with CT/MRI." @default.
• W2102393399 created "2016-06-24" @default.
• W2102393399 creator A5011372017 @default.
• W2102393399 creator A5011844380 @default.
• W2102393399 creator A5022226042 @default.
• W2102393399 creator A5023353633 @default.
• W2102393399 creator A5026573275 @default.
• W2102393399 creator A5030727384 @default.
• W2102393399 creator A5046167689 @default.
• W2102393399 creator A5048723580 @default.
• W2102393399 creator A5054303361 @default.
• W2102393399 creator A5054391751 @default.
• W2102393399 creator A5056074989 @default.
• W2102393399 creator A5066158692 @default.
• W2102393399 creator A5070321337 @default.
• W2102393399 creator A5074604036 @default.
• W2102393399 creator A5085601211 @default.
• W2102393399 creator A5087322137 @default.
• W2102393399 date "2013-10-01" @default.
• W2102393399 modified "2023-10-17" @default.
• W2102393399 title "Glucagon-like peptide-1 receptor imaging for the localisation of insulinomas: a prospective multicentre imaging study" @default.
• W2102393399 cites W1945989183 @default.
• W2102393399 cites W1978063542 @default.
• W2102393399 cites W1981189234 @default.
• W2102393399 cites W1986873494 @default.
• W2102393399 cites W1990830085 @default.
• W2102393399 cites W2013889051 @default.
• W2102393399 cites W2042416928 @default.
• W2102393399 cites W2044616670 @default.
• W2102393399 cites W2045644037 @default.
• W2102393399 cites W2045681528 @default.
• W2102393399 cites W2059424770 @default.
• W2102393399 cites W2061192940 @default.
• W2102393399 cites W2062961075 @default.
• W2102393399 cites W2080916065 @default.
• W2102393399 cites W2097855568 @default.
• W2102393399 cites W2102407781 @default.
• W2102393399 cites W2116145810 @default.
• W2102393399 cites W2116553674 @default.
• W2102393399 cites W2121345881 @default.
• W2102393399 cites W2140004965 @default.
• W2102393399 cites W2164003774 @default.
• W2102393399 cites W2318614358 @default.
• W2102393399 cites W2337046339 @default.
• W2102393399 cites W4238277609 @default.
• W2102393399 doi "https://doi.org/10.1016/s2213-8587(13)70049-4" @default.
• W2102393399 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24622317" @default.
• W2102393399 hasPublicationYear "2013" @default.
• W2102393399 type Work @default.
• W2102393399 sameAs 2102393399 @default.
• W2102393399 citedByCount "147" @default.
• W2102393399 countsByYear W21023933992013 @default.
• W2102393399 countsByYear W21023933992014 @default.
• W2102393399 countsByYear W21023933992015 @default.
• W2102393399 countsByYear W21023933992016 @default.
• W2102393399 countsByYear W21023933992017 @default.
• W2102393399 countsByYear W21023933992018 @default.
• W2102393399 countsByYear W21023933992019 @default.
• W2102393399 countsByYear W21023933992020 @default.
• W2102393399 countsByYear W21023933992021 @default.
• W2102393399 countsByYear W21023933992022 @default.
• W2102393399 countsByYear W21023933992023 @default.
• W2102393399 crossrefType "journal-article" @default.
• W2102393399 hasAuthorship W2102393399A5011372017 @default.
• W2102393399 hasAuthorship W2102393399A5011844380 @default.
• W2102393399 hasAuthorship W2102393399A5022226042 @default.
• W2102393399 hasAuthorship W2102393399A5023353633 @default.
• W2102393399 hasAuthorship W2102393399A5026573275 @default.
• W2102393399 hasAuthorship W2102393399A5030727384 @default.
• W2102393399 hasAuthorship W2102393399A5046167689 @default.
• W2102393399 hasAuthorship W2102393399A5048723580 @default.
• W2102393399 hasAuthorship W2102393399A5054303361 @default.
• W2102393399 hasAuthorship W2102393399A5054391751 @default.
• W2102393399 hasAuthorship W2102393399A5056074989 @default.
• W2102393399 hasAuthorship W2102393399A5066158692 @default.
• W2102393399 hasAuthorship W2102393399A5070321337 @default.
• W2102393399 hasAuthorship W2102393399A5074604036 @default.
• W2102393399 hasAuthorship W2102393399A5085601211 @default.
• W2102393399 hasAuthorship W2102393399A5087322137 @default.
• W2102393399 hasBestOaLocation W21023933991 @default.
• W2102393399 hasConcept C126322002 @default.
• W2102393399 hasConcept C126838900 @default.
• W2102393399 hasConcept C188816634 @default.
• W2102393399 hasConcept C2775842073 @default.
• W2102393399 hasConcept C2778764654 @default.
• W2102393399 hasConcept C2780053029 @default.
• W2102393399 hasConcept C2984398910 @default.
• W2102393399 hasConcept C2989005 @default.
• W2102393399 hasConcept C71924100 @default.
• W2102393399 hasConceptScore W2102393399C126322002 @default.
• W2102393399 hasConceptScore W2102393399C126838900 @default.
• W2102393399 hasConceptScore W2102393399C188816634 @default.
• W2102393399 hasConceptScore W2102393399C2775842073 @default.
• W2102393399 hasConceptScore W2102393399C2778764654 @default.
• W2102393399 hasConceptScore W2102393399C2780053029 @default.
• W2102393399 hasConceptScore W2102393399C2984398910 @default.
• W2102393399 hasConceptScore W2102393399C2989005 @default.
• W2102393399 hasConceptScore W2102393399C71924100 @default.

• next